Abstract Sphingosine kinases (SphKs) catalyze the phosphorylation of sphingosine to sphingosine-1-phosphate (S1P). Together with other sphingolipid metabolizing enzymes, SphKs regulate the balance of the lipid mediators, ceramide, sphingosine, and S1P. The ubiquitous mediator S1P regulates cellular functions such as proliferation and survival, cytoskeleton architecture and Ca 2+ homoeostasis, migration, and adhesion by activating specific high-affinity G-protein-coupled receptors or by acting intracellularly. In mammals, two isoforms of SphK have been identified. They are activated by G-protein-coupled receptors, receptor tyrosine kinases, immunoglobulin receptors, cytokines, and other stimuli. The molecular mechanisms by which SphK1 and SphK2 are specifically regulated are complex and only partially understood. Although SphK1 and SphK2 appear to have opposing roles, promoting cell growth and apoptosis, respectively, they can obviously also substitute for each other, as mice deficient in either SphK1 or SphK2 had no obvious abnormalities, whereas double-knockout animals were embryonic lethal. In this review, our understanding of structure, regulation, and functional roles of SphKs is updated and discussed with regard to their implication in pathophysiological and disease states.
Introduction
Sphingosine kinases (SphKs) catalyze the phosphorylation of sphingosine, thereby forming the lysophospholipid mediator, sphingosine-1-phosphate (S1P; Maceyka et al. 2002; Hait et al. 2006; Taha et al. 2006a; Wattenberg et al. 2006) . More than 30 years ago, the SphK-S1P pathway was considered as sphingolipid degradation pathway, as cleavage of S1P by S1P lyase leads to irreversible breakdown of the sphingosine backbone . Cellular signaling by S1P was first described in 1991 by Zhang et al. (1991) . In 1993, Olivera and Spiegel reported that SphK activity and S1P production were regulated by extracellular mediators, namely, serum and platelet-derived growth factor (PDGF). Since then, our knowledge about S1P as first and second messenger has grown rapidly. S1P is now recognized as an important, nearly ubiquitous regulator of cell proliferation and survival, migration and chemotaxis, cytoskeletal architecture, cell-tocell contacts and adhesion, Ca 2+ homoeostasis, and Ca
2+
There is a family of five S1P-GPCRs (S1P 1-5 ), which have a high homology to GPCRs for the related lysophosphatidic acid (LPA), and three other putative, less well-characterized S1P-GPCRs (GPR3, GPR6, and GPR12; Chun et al. 2002; Anliker and Chun 2004; Hla 2004; Ishii et al. 2004 ; Meyer zu Heringdorf and Jakobs 2006). S1P-GPCRs play a role in vasculogenesis and regulation of vascular tone, chemotaxis and lymphocyte trafficking, inflammation, and immunity (Anliker and Chun 2004; Hla 2004; Ishii et al. 2004 ; Meyer zu Heringdorf and Jakobs 2006). In addition, there is substantial functional evidence for intracellular actions of S1P, in particular, regulation of Ca 2+ homoeostasis (reviewed in Young and Nahorski 2001; Meyer zu Heringdorf 2004) .
Extra-and intracellular levels of S1P are tightly regulated by SphKs and S1P degrading enzymes. Diverse membrane receptors and signaling molecules stimulate SphK activity and expression, and the mechanisms by which SphK isoenzymes are specifically regulated are becoming increasingly clear, although there are still many open questions (Hait et al. 2006; Taha et al. 2006a ), see below. Degradation of S1P occurs by dephosphorylation, catalyzed by S1P phosphatases (SPPs) and lipid phosphate phosphatases (LPPs), or by cleavage, catalyzed by S1P lyase (Brindley 2004; Saba and Hla 2004; Pyne et al. 2005) . The non-specific LPPs dephosphorylate phosphatidic acid, LPA, ceramide-1-phosphate, and S1P, thereby generating diacylglycerol (DAG), monoacylglycerol, ceramide, and sphingosine, respectively (Brindley 2004; Pyne et al. 2005) . LPPs are integral membrane proteins that are localized at the plasma membrane as well as intracellular membranes, their catalytic centers face the extracellular space and the luminal side of organelles, and they apparently can regulate extracellular as well as intracellular levels of lipid phosphates, including S1P (Brindley 2004; Pyne et al. 2005) . The two known SPPs and S1P lyase are also integral membrane proteins and are localized at the endoplasmic reticulum. The catalytic center of SPPs has been predicted to face the luminal side, whereas that of S1P lyase is directed towards the cytosol (Brindley 2004; Ikeda et al. 2004 ). Both phosphatases and lyase regulate extraand intracellular levels of S1P and contribute to the cellular balance of relative levels of S1P, sphingosine, and ceramide (Mandala et al. 2000; Johnson et al. 2003; Reiss et al. 2004; Schwab et al. 2005) .
Importantly, S1P, sphingosine, and ceramide can be interconverted by the sequential actions of SPPs and ceramide synthases, ceramidases, and SphKs, respectively (Fig. 1) . Ceramide is furthermore formed by sphingomyelinases in response to many inducers of stress, such as heat, UV radiation, hypoxia/reperfusion, cytokines, or chemotherapeutic agents. Ceramide binds to several targets ( Fig. 1 ) and appears to be involved in cellular stress responses, in particular, apoptosis (for review, see Hannun and Obeid 2002) . Recently, the importance of ceramide-1-phosphate and its formation by ceramide kinase has become more prominent, although still little is known about this mediator (Chalfant and Spiegel 2005) . For more extensive review of sphingolipid metabolism, see Hannun et al. (2001) , Hannun and Obeid (2002) , Ogretmen and Hannun (2004) , Futerman and Riezman (2005) .
Structural characteristics of SphKs
Molecular identification of mammalian SphKs started with purification of rat kidney SphK to apparent homogeneity, which resulted in a protein of 49 kDa ). Subsequently, mouse SphK1a and SphK1b variants, with 382 and 388 amino acids, respectively, were cloned and characterized . The human SphK1 (Melendez et al. 2000; Nava et al. 2000; Pitson et al. 2000a) was found to have a high homology to the mouse enzyme (see Fig. 2 ). A second isoform of SphK was identified by blast searches of the expressed sequence tag database using the mouse SphK1 sequence (Liu et al. 2000a ; Fig. 3 ). SphK2 is in large parts homologous to SphK1 but has ∼240 additional amino acids that are located at the N terminus and in the center of the enzyme, respectively (Liu et al. 2000a) . SphKs are evolutionary highly conserved and have been identified for example in Saccharomyces cerevisiae, Dictyostelium discoideum, Caenorhabditis elegans, Drosophila melanogaster, and Arabidopsis thaliana (for review, see Taha et al. 2006a) . Five conserved domains (C1-C5) have been identified within SphKs, of which C1-C3 contain the DAG kinase catalytic domain, which is also found in DAG kinases and ceramide kinase, whereas C4 appears to be unique in SphKs Taha et al. 2006a ).
SphK1 and SphK2 are differentially expressed in mammals. Northern blot analysis and quantitative PCR revealed that during embryonic development of the mouse, SphK1 expression was high at embryonic day 7 and decreased thereafter, whereas SphK2 expression increased gradually up to embryonic day 17 (Liu et al. 2000a; Kihara et al. 2006) . In adult mouse tissues, SphK1 expression was highest in lung, spleen, kidney, and blood, whereas SphK2 was predominantly found in liver, kidney, brain, and heart (Liu et al. 2000a; Billich et al. 2003; Kihara et al. 2006 ). However, SphK activity can be measured in all mouse tissues (Fukuda et al. 2003; Billich et al. 2003) .
Furthermore, the two mammalian SphK isoforms differ with respect to their substrate specificity and favored conditions. SphK1 clearly preferred D-erythro-sphingosine and D-erythro-dihydrosphingosine over other substrates, whereas SphK2 also phosphorylated phytosphingosine, DL-threo-dihydrosphingosine (threo-DHS) and, most importantly, FTY720 (Liu et al. 2000a; Billich et al. 2003) . FTY720 (fingolimod) is a novel immunosuppressive that, after being phosphorylated by SphK, interacts with S1P-GPCR, thereby interfering with lymphocyte trafficking (Brinkmann et al. 2004) . Interestingly, FTY720 caused lymphopenia in mice lacking SphK1 but was inactive in mice lacking SphK2, which demonstrates the requirement of SphK2 for metabolic activation of this pro-drug (Allende et al. 2004; Kharel et al. 2005; Zemann et al. 2006) . Ceramide, DAG, or phosphatidylinositol were not phosphorylated by SphKs. Threo-DHS and N,N-dimethylsphingosine (DMS) were competitive inhibitors of SphK1. In contrast, threo-DHS was phosphorylated by SphK2, albeit weakly, and DMS was a non-competitive inhibitor of SphK2 (Liu et al. 2000a ). The K m values of both SphK isoforms for D-erythro-sphingosine were in the range of 5-15 μM, the K m of SphK1 for ATP was 80-90 μM Liu et al. 2000a; Pitson et al. 2000a; Billich et al. 2003) . Interestingly, the V max of SphK1 was decreased by high salt concentrations (>50 mM NaCl or KCl), whereas that of SphK2 was enhanced under these conditions (Liu et al. 2000a) . In contrast, Triton X-100 (0.05-0.5%) enhanced SphK1 activity while suppressing SphK2 (Liu et al. 2000a ). This differential activation of SphK1 and SphK2 by salt and detergents allows the separate measurement of the two kinases in cell and tissue lysates.
In the human genome, SPHK1 is localized to chromosome 17 (17q25.2) and SPHK2 to chromosome 19 (19q13.2) . Of both SphK isoforms, several alternatively spliced variants that differ at their N termini have been identified in man, mouse, and rat (Billich et al. 2003; Okada et al. 2005; Kihara et al. 2006 ). In the rat, six alternative first exons for SphK1 mRNA have been described, which were located within a CpG island serving as a template for the multiple SphK1 variants (Imamura et al. 2001) . In man, at least three variants of SphK1 with 384, 399, and 470 amino acids [named SphK1a, SphK1b, and SphK1c ] and two variants of SphK2 with 618 and 654 amino acids [named SphK-S and SphK-L or SphK2a and SphK2b (Okada et al. 2005; Venkataraman et al. 2006) ], respectively, have been identified (see Figs. 2 and 3 ). Enzyme kinetics were found to be similar for the respective SphK1 and SphK2 variants (Billich et al. 2003) . However, mouse SphK1 variants differed in stability and other aspects ). The murine SphK1b protein was unstable compared to SphK1a, displayed abnormal fast mobility in SDS gel electrophoresis, and formed homo-oligomers. Furthermore, mouse SphK1b was palmitoylated at its extra two Nterminal cysteine residues and localized to the plasma membrane where it was degraded by proteasome. In contrast, mouse SphK1a was a stable protein, localized mostly cytosolic and degraded only when membrane-bound . In agreement, human SphK1b was located at the plasma membrane to a much greater extent than human SphK1a, whereas human SphK1c appeared to be associated with small membranous or vesicular compartments throughout the cytosol Glycosphingolipids Fig. 1 Metabolic interconversion of C1P, ceramide, sphingosine, and S1P. Ceramide is in the center of sphingolipid metabolism, generated by de novo-sphingolipid synthesis or by sphingomyelin degradation. Ceramide is furthermore the starting point for synthesis of glycosphingolipids (Hannun et al. 2001; Ogretmen and Hannun 2004) . Ceramide interacts with protein phosphatase-1 and phosphatase-2A (PP1, PP2A), PKCζ, Raf-1, cathepsin D, and the kinase suppressor of Ras (Snook et al. 2006) . Sphingosine inhibits PKC. S1P activates specific GPCR as well as unknown intracellular target(s). C1P, formed from ceramide by ceramide kinase (CERK) was recently shown to directly activate cPLA 2 (Pettus et al. 2004) . For further details, see text found to be the major form in several human cell lines and tissues (Okada et al. 2005) . Whereas SphK2-S/SphK2a induced apoptosis through its putative BH3 domain (Liu et al. 2003) and inhibited DNA synthesis both in the absence and presence of serum (Okada et al. 2005 ), SphK2-L/ SphK2b decreased DNA synthesis only in the absence of serum, indicating a differential role of both isoforms (Okada et al. 2005) . Furthermore, serum deprivation induced the expression of SphK2-L/SphK2b and its shuttling into the nucleus, and siRNA depletion of SphK2 and has one additional amino acid compared to the first described mSphK1a, whereas NM_011451.1 corresponds to mSphK1b ). The human SphK1 variants, represented by AF200328.1, NM_021972.2, and NM_182965.1, have recently been named SphK1a, SphK1b, and SphK1c, respectively . Box Conserved DAG kinase catalytic domain. Encircled 1 Glycine that is important for catalytic activity; mutation to aspartate leads to a dominant negative enzyme (Pitson et al. 2000b) . Encircled 2 Aspartate that is required for sphingosine binding (Yokota et al. 2004) . Encircled 3 Site for phosphorylation by ERK . Encircled 4 Residues involved in phosphatidylserine binding (Stahelin et al. 2005) . Blue line ATP binding site . Red line Ca 2+ /Calmodulin binding site (Sutherland et al. 2006) . Black line TRAF2 binding site (Xia et al. 2002) Fig. 3 Amino acid sequences of various human (h) and mouse (m) SphK2 variants. The human SphK2 variants, represented by AF245447 and AL136701.1, correspond to SphK2-S and SphK2-L (Okada et al. 2005) or SphK2a and SphK2b , respectively. Box Conserved diacyl glycerol kinase catalytic domain. Encircled 1 Glycine that is important for catalytic activity (corresponds to 1 in SphK1; Yoshimoto et al. 2003; Maceyka et al. 2005) . Blue line Nucleotide-binding motif. Red line Ca 2+ /Calmodulin binding site (Sutherland et al. 2006) . Black line BH3 domain (Liu et al. 2003) . Green line Nuclear localization signal protected the cells from serum deprivation-and druginduced apoptosis (Okada et al. 2005) . Together with a previous report describing SphK2-S/SphK2a as pro-apoptotic BH3 only-protein (Liu et al. 2003) , these data indicate that SphK2 is involved in the regulation of apoptosis (Okada et al. 2005 ; see below). We have identified another variant of human SphK2 (gene bank accession number EF107108) that contains 761 amino acids and differs from the previously described SphK2 variants by a prolonged N-terminal extension and a modified C terminus (SphK2c, Fig. 3 ). Compared to SphK2-S/SphK2a, which is organized in five exons on chromosome 19, SphK2-L/SphK2b comprises two additional exons in 5′ direction, whereas SphK2c has a 5′-extension of exon 1 and a sixth exon encoding the C terminus (Fig. 4) . Expression of the full-length SphK2c mRNA in HEK-293 and HL-60 cells was confirmed by PCR (data not shown). However, we were not able to express the full-length protein so far.
SphKs have a DAG kinase catalytic domain (see Figs. 2 and 3), which contains the nucleotide binding site (consensus sequence SGDGX 17-21 K; Pitson et al. 2002) . By comparison with DAG kinases, a glycine residue (glycine-82 in human SphK1a, position 182 in Fig. 2 ) was identified in SphK1 as essential for catalytic activity. Mutation to aspartate (G82D mutation) resulted in a catalytic inactive enzyme that acted in a dominant negative manner and has been widely used to dissect SphK signaling pathways (Pitson et al. 2000b ). The corresponding glycine in SphK2 (glycine-212 in SphK2-S/SphK2a, position 310 in Fig. 3 ) was similarly required for enzymatic activity (Yoshimoto et al. 2003; Maceyka et al. 2005) . Another glycine (glycine-133 of human SphK1a, position 213 in Fig. 2 ) furthermore regulated SphK1 catalytic activity; mutation to aspartate decreased, whereas mutation to alanine enhanced activity (Pitson et al. 2001) . Sphingosine binding was assigned to the C4 domain (Yokota et al. 2004) . In mouse SphK1a, aspartate-177 (position 278 in Fig. 2 ) was particularly important, as its mutation to asparagine enhanced the K m for sphingosine, but not ATP, and dramatically decreased enzyme activity (Yokota et al. 2004 ).
Regulation of SphKs
SphK activity in general is stimulated for example by GPCR agonists (muscarinic receptor agonists, formyl peptide, nucleotides, LPA and S1P, bradykinin), agonists at receptor tyrosine kinases [PDGF, epidermal growth factor (EGF), nerve growth factor (NGF), vascular endothelial growth factor (VEGF)], cross-linking of immunoglobulin receptors, tumor necrosis factor-α (TNF-α), transforming growth factor-β (TGF-β), interleukins (ILs), Ca 2+ increasing agents, and phorbol ester (reviewed in Maceyka et al. 2002; Meyer zu Heringdorf 2004; Taha et al. 2006a ). Whereas many stimuli cause a rapid, transient stimulation of SphK activity, most likely by posttranslational modification or by affecting its localization, other agents induce a biphasic course of SphK activation, with a first rapid increase in enzymatic activity that is followed by a prolonged transcriptional upregulation. Upregulation of SphK1 expression was induced for example by estrogen (Sukocheva et al. 2003) , 1,25-dihydroxyvitamin D3 (Manggau et al. 2001) , EGF (Döll et al. 2005) , and histamine (Huwiler et al. 2006) .
The pathways and molecular mechanisms by which SphK isoforms are acutely activated in a specific manner are not entirely clear. SphK1 appears to be regulated by protein-protein interactions, phosphorylation, phosphatidic acid, Ca 2+ , and subcellular localization.
Regulation of SphK1 by TNF-α, phosphorylation, and phosphatidylserine binding Activation of SphK1 by TNF-α, an important pro-inflammatory cytokine, required its binding to TNF receptor-associated factor-2 (TRAF2; Xia et al. 2002) . Deletion of the TRAF2 binding consensus site, PPEE (Fig. 2) , abrogated the interaction of SphK1 with TRAF2 and the stimulation of SphK1 by TNF-α but not by phorbol ester (Xia et al. 2002) . Phorbol ester, via protein kinase C, stimulated phosphorylation of SphK1 and its translocation to the plasma membrane (Johnson et al. 2002) . Both TNF-α and phorbol ester stimulated phosphorylation of SphK1 by extracellular signal-regulated kinase (ERK1/2) at serine-225 (position 325 in Fig. 2 ), and this phosphorylation was required for agonist stimulation of SphK activity and translocation of SphK1 to the plasma membrane . On the other hand, SphK1 was also required for TNF-α-stimulated ERK activation (Pitson et al. 2000b) , indicating some complexity of ERK/ SphK1 interaction. Interestingly, in vitro phosphorylation of SphK1 greatly enhanced its activity , but the basal cellular S1P production by the non-phosphorylat- able SphK1-S225A mutant was not much lower than that caused by the wild-type enzyme . Whereas overexpression of wild-type SphK1 enhanced growth of NIH3T3 cells, expression of the SphK1-S225A mutant stimulated growth and colony formation only when it was artificially targeted to the plasma membrane. These data suggest that the localized production of S1P at the plasma membrane, rather than the overall enhancement of SphK activity, mediated the oncogenic effect . The data furthermore suggest that phosphorylation at serine-225 does not primarily stimulate SphK1 activity (as suggested in Pitson et al. 2003) , but rather the SphK1 membrane translocation (as shown in Pitson et al. 2005 ).
Other authors reported that plasma membrane-targeted SphK1 reduced the growth of 3T3 L1 fibroblasts by delaying exit from G 0 /G 1 phase and protected the cells from apoptosis induced by serum withdrawal (SafadiChamberlain et al. 2005 ). Plasma-membrane-localized SphK1 can cause S1P release into the medium, leading to activation of S1P-GPCR. The cellular effects caused by this process are cell-type specific depending on the expressed S1P-GPCRs and their respectively signaling (see "Insideout and intracellular signaling by SphKs"). Recently, a mechanism for membrane targeting of SphK1 has been suggested, which involves phosphatidylserine binding (Stahelin et al. 2005) . SphK activity was enhanced by acidic phospholipids, particularly phosphatidylserine, and SphK1 selectively bound to this lipid in vitro (Olivera et al. 1996; Stahelin et al. 2005 ). The conserved threonine-54 and asparagine-89 (positions 154 and 189 in Fig. 2 ) were essential for phosphatidylserine binding as well as plasma membrane translocation and S1P secretion in intact cells (Stahelin et al. 2005 ). Mutation of serine-225 to alanine did not prevent, as reported by Pitson et al. (Pitson et al. 2003) , but reduced plasma membrane translocation of SphK1 and affected phosphatidylserine binding. A model was suggested in which phosphorylation of serine-225 caused exposure of threonine-54 and asparagine-89 and/or other phosphatidylserine-binding residues, thereby facilitating membrane association (Stahelin et al. 2005) . Enzymatic activity would be enhanced in this model by bringing SphK1 in close contact to its substrate, sphingosine, and by the stimulatory action of phosphatidylserine.
Regulation of SphK1 by phospholipase D Using antisense nucleotides against phospholipase D (PLD) 1, it was demonstrated that SphK1 was activated via PLD1 in human mast cells (Melendez and Khaw 2002) . In agreement, recombinant purified SphK1 bound to phosphatidic acid, the interaction site being located within the C-terminal half of the enzyme (Delon et al. 2004 ). SphK1 furthermore colocalized with PLD1 at endosomal compartments, although no evidence for a direct interaction of both enzymes was obtained, indicating that SphK1 interacted with phosphatidic acid but not with PLD1 (Delon et al. 2004) . Interestingly, in a mixture of separately obtained cytosol and membranes, SphK1 translocated from the cytosol to the membranes upon addition of PLD from Streptomyces chromofuscus in the presence of Ca 2+ (Ca 2+ was required for activation of the bacterial enzyme; Delon et al. 2004) . ATP, which alone induced translocation of a small proportion of SphK1, furthermore enhanced the PLD effect, suggesting that phosphorylation might play an additional role (Delon et al. 2004 ).
Regulation of SphK activity by Ca
2+ Several data suggest that SphKs are involved in receptor-induced Ca 2+ mobilization from intracellular stores (see below and Meyer zu Heringdorf 2004). However, some reports suggest that SphKs, in particular SphK1, also require Ca 2+ for catalytic activity. Chelation of intracellular Ca 2+ inhibited formyl peptide-, nucleotide-, and M 3 receptor-stimulated S1P production in HL-60 granulocytes and HEK-293 cells, respectively, whereas Ca 2+ increasing agents enhanced basal S1P formation (Alemany et al. 2000) . On the other hand, SphK activity was required in these cells for Ca 2+ mobilization by the above-mentioned receptors (Meyer zu Heringdorf et al. 1998; Alemany et al. 1999) . In PC12 cells, Ca 2+ influx via voltage-gated Ca 2+ channels elevated S1P levels, whereas overexpression of SphK1 clearly enhanced noradrenaline release, suggesting that SphK1 sensed and augmented the Ca 2+ increase (Alemany et al. 2001) . SphK1 binds to Ca 2+ /calmodulin ); however, a direct activation of the enzyme by Ca 2+ has not been demonstrated so far. It has been suggested that Ca 2+ / calmodulin did not stimulate the activity but the translocation of SphK1 to the plasma membrane, as M 3 receptor-stimulated SphK1 translocation was inhibited by a calmodulin inhibitor in SH-SY5Y cells (Young et al. 2003) . Several putative calmodulin-binding sites have been suggested by sequence analysis of SphK1 Taha et al. 2006a) . Recently, however, the calmodulin-binding site was ascribed to residues 191-206 of human SphK1a (positions 292-306 in Fig. 2) . Without a functional calmodulin-binding site, SphK1 did not translocate to the plasma membrane upon stimulation with phorbol ester, but its catalytic activity and phosphorylation remained intact (Sutherland et al. 2006 ).
Other mechanisms of SphK1 regulation Several proteins have been identified that directly interact with SphK1, for example, a protein kinase A anchoring protein-related protein (also named SphK-interacting protein), aminoacylase-1, platelet endothelial cell adhesion molecule-1, RPK118, and others (reviewed in Taha et al. 2006a ). The functional significance of these interactions is not fully clear at present. Hepatocyte growth factor required the tyrosine phosphatase, Shp-2, for activation of SphK1 in embryonic fibroblasts, and Shp-2 was co-immunoprecipitated with SphK1, indicating a direct interaction (Duan et al. 2006) . Recently, a negative regulation of SphK1 by TNF-α has been described (Taha et al. 2005) . Prolonged treatment of MCF-7 cells with TNF-α initiated apoptosis, which involved the disruption of lysosomes and release of cathepsin B to the cytosol, and this cysteine protease cleaved SphK1 at multiple sites, thereby downregulating the pro-survival enzyme during the apoptotic process (Taha et al. 2005 (Taha et al. , 2006b ).
Regulation of SphK1 and SphK2 by directed localization
Looking at the mechanisms by which SphKs can be activated, it comes to attention that SphK1 has a substantial basal activity, and stimulation with agonists often leads to only ∼1.5-to 2-fold increase in catalytic activity. Therefore, SphK1 signaling might rather be regulated by translocation to subcellular compartments than by a major increase in its catalytic activity (discussed in Wattenberg et al. 2006) . Under resting conditions, SphK1 is a cytosolic enzyme that is translocated to the plasma membrane, as described above, by several stimuli. However, SphK1 also translocated to perinuclear, probably endosomal, compartments upon induction of PLD1 (Delon et al. 2004 ). In human macrophages, SphK1 was recruited to nascent phagosomes, and this process was independent of its catalytic activity or phosphorylation at serine-225 but dependent on Ca 2+ (Thompson et al. 2005) . Interestingly, both SphK1 translocation to phagosomes and macrophage SphK activity were inhibited by Mycobacterium tuberculosis, which inhibits phagosome maturation and is able to survive within macrophages. SphK inhibition by threo-DHS also blocked phagosome maturation, suggesting that the effect of M. tuberculosis on SphK contributed to survival of the pathogen within macrophages (Malik et al. 2003; Thompson et al. 2005) . Two nuclear export sequences were identified in SphK1, and deletion of these sequences or inhibition of nuclear export caused nuclear accumulation of the enzyme, indicating that SphK1 can shuttle between cytosol and nucleus (Inagaki et al. 2003) . SphK2, on the other hand, has been identified predominantly in the cytosol and nucleus. In HeLa and COS-7, but not HEK-293 cells, SphK2 was localized predominantly in the nucleus, and a nuclear localization signal was mapped to the N-terminal part of SphK2 (see Fig. 3 ; Igarashi et al. 2003) . Studies with SphK1 and SphK2 variants suggest that the N terminus has a major impact on subcellular localization . Furthermore, serum depletion promoted the association of SphK2 with the endoplasmic reticulum . Taken together, these data are in agreement with an extra-as well as intracellular signaling role of S1P.
Regulation of SphK2 First reports suggest that SphK2 can also be regulated by agonists. EGF stimulated SphK2 in HEK-293 and MDA-MB-453 breast cancer cells . Downregulation of SphK2 completely eliminated migration towards EGF in the breast cancer cells, whereas it had no effect in HEK-293 cells, indicating cell type-specific signaling by SphK2. SphK2 furthermore interacted directly with the cytoplasmic region of the IL-12 receptor subunit, IL-12Rβ1, and expression of dominant negative SphK2 suppressed IL-12-stimulated production of interferon-γ (Yoshimoto et al. 2003) . In mast cells, it was recently shown that the immunoglobulin E receptor, FcɛRI, not only activated SphK1, as reported before, but also SphK2 (Olivera et al. 2006 ). The Src tyrosine kinase, Fyn, was required for stimulation of SphK1 and SphK2 by FcɛRI and for basal activity of SphK2. Furthermore, Fyn was required for IL-3-induced activation of SphK1 but not SphK2. Finally, both SphK1 and SphK2 directly interacted with the Fyn kinase (Olivera et al. 2006) . Altogether, the regulation of SphK2 appears to be complex and requires further investigation.
Inside-out and intracellular signaling by SphKs
Cellular S1P, produced by SphKs, can be exported and act on S1P-GPCR, a process which is called inside-out signaling . On the other hand, substantial evidence supports an additional intracellular role of S1P (discussed in Meyer zu Heringdorf 2004; Chalfant and Spiegel 2005) . Overexpression of SphK1 induced stress fiber formation via G 12/13 -proteins in NIH3T3 cells, indicating the involvement of S1P-GPCR. In contrast, SphK1 overexpression stimulated proliferation and protected from apoptosis even in fibroblasts derived from S1P 2/3 double knockout mice, in which neither S1P 4 nor S1P 5 were expressed (Ishii et al. 2002) and signaling by S1P 1 was blocked by pertussis toxin (Olivera et al. 2003) , suggesting that intracellular S1P mediated proliferation and survival in mouse embryonic fibroblasts. In contrast, NGF, via its TrkA receptor, stimulated plasma membrane translocation of SphK1 and activated the S1P 1 and S1P 2 receptors in a SphK1-dependent manner in PC12 and dorsal root ganglion cells, and NGF-induced neurite extension was suppressed by downregulation of S1P 1 (Toman et al. 2004 ). Cross-linking of FcɛRI in mast cells not only activated SphK but also stimulated S1P secretion and activation of S1P 1 and S1P 2 , which were internalized upon FcɛRI activation. S1P 1 was required for migration of mast cells towards antigen, whereas S1P 2 was required for degranulation (Jolly et al. 2004) . These data, however, are in contrast to the hypothesis of Melendez et al., who suggested that Ca 2+ release by intracellular S1P was involved in SphK1-dependent mast cell degranulation (Melendez and Khaw 2002) , and to the report by Spiegel et al., demonstrating that S1P export via an ATP binding cassette (ABC) transporter was involved in migration but not degranulation of mast cells (Mitra et al. 2006) . S1P signaling inside-out via the S1P 1 receptor furthermore contributed to PDGF-stimulated cell migration (Hobson et al. 2001) , although the mutual cross-activation of the S1P 1 and PDGF receptors might also be based on a receptor signaling platform (Waters et al. 2006 ). Recently, it was shown that insulin-like growth factor (IGF) promoted the translocation of SphK1 to the plasma membrane, increased SphK activity, and induced internalization of the S1P 1 receptor (El Shewy et al. 2006) . IGF-stimulated ERK activation was inhibited by SphK1 silencing and the S1P 1/3 antagonist, VPC23019, indicating that both SphK1 and S1P 1 were required for ERK activation by IGF (El Shewy et al. 2006) .
Not only S1P but also SphK1 can apparently be released from cells (Ancellin et al. 2002; . SphK1 was constitutively excreted by vascular endothelial cells and HEK-293 cells by a nonclassical secretory pathway (Ancellin et al. 2002) . Of SphK1 and SphK2 variants transfected in HEK-293 cells, ∼3.5% of SphK1a but less than 1% of SphK1b and SphK1c were secreted, whereas SphK2 was not secreted by vascular endothelial or HEK-293 cells . As haematopoietic cells including platelets express SphKs, it was not surprising that mouse and human blood contained substantial SphK activity. Plasma S1P levels in SphK1 null mice were less than half of control mice, indicating that SphK1 contributed to the S1P gradient between plasma and tissues . Although SphK activity in mouse platelet-poor plasma was comparably low, it was suggested that plasma contained soluble SphK1 . Human plasma contained even lower SphK activity, but this activity could be attributed to SphK1 by immunoprecipitation .
Recent interest has focused on the mechanisms by which S1P can be extruded from cells. By studying platelets, Kobayashi et al. came to the conclusion that two independent S1P releasing systems might exist in the platelet plasma membrane, an ATP-dependent system stimulated by thrombin, and an ATP-independent system stimulated by Ca 2+ (Kobayashi et al. 2006) . ATP-and thrombin-stimulated S1P release were inhibited by the ABC transporter inhibitor, glyburide, whereas Ca 2+ -stimulated release was not (Kobayashi et al. 2006) . Very recently, the involvement of the ABC transporter, ABCC1, in cellular S1P release was demonstrated in mast cells using specific inhibitors and siRNA (Mitra et al. 2006) . S1P export by ABCC1 was required for migration but not degranulation of mast cells (Mitra et al. 2006) .
Despite the many examples for inside-out signaling by SphKs and S1P, there is compelling evidence for an additional intracellular role of S1P (discussed, e.g., in Spiegel and Milstien 2003; Meyer zu Heringdorf 2004; Chalfant and Spiegel 2005 ). There are three major lines of evidence for intracellular signaling by S1P. First of all, signaling by SphKs and S1P has been demonstrated in organisms such as yeast, Dictyostelium, plant, flies, and worms, whereas S1P-GPCR apparently developed later in evolution, suggesting that other S1P targets must exist (Saba and Hla 2004) . Second, the intracellular localization of SphKs, in particular, the localization of SphK2 in the nucleus, the translocation of SphK1 to intracellular sites by PLD1 and during phagocytosis, and the localization of S1P lyase and SPPs at the endoplasmic reticulum, suggest a localized, intracellular S1P signaling (see above). This is supported by the fact that for inside-out signaling, SphK1 is shuttled to the plasma membrane. Third, several studies described intracellular S1P actions that were not imitated by extracellular S1P and could not be attributed to S1P-GPCR signaling (reviewed in Meyer zu Heringdorf 2004; Chalfant and Spiegel 2005) . Intracellular S1P, released from caged S1P by photolysis, mobilized Ca 2+ from thapsigarginsensitive stores even in cells that did not express the known S1P-GPCR and in which extracellular S1P was inactive (Meyer zu Heringdorf et al. 2003) . A role for SphK in the regulation of Ca 2+ was furthermore shown recently in NIH3T3 cells, in which SphK2 translocated to the endoplasmic reticulum under serum starvation, and basal cytosolic Ca 2+ levels were elevated under serum-free conditions in SphK2-overexpressing cells . A role for SphK in agonist-and receptor-stimulated Ca 2+ mobilization has been shown predominantly by using not only the non-specific SphK inhibitors, threo-DHS and DMS (many publications; for review, see Meyer zu Heringdorf 2004), but also by SphK1 antisense (Melendez and Khaw 2002; Melendez and Ibrahim 2004) . SphK1 antisense abrogated the fast increase in intracellular Ca 2+ ([Ca 2+ ] i ), which was required for degranulation in mast cells (Melendez and Khaw 2002) . However, inside-out signaling via S1P 2 was later shown to drive degranulation of mast cells in response to FcɛRI-mediated SphK1 activation (Jolly et al. 2004) , although this has been questioned (Mitra et al. 2006 ; see above). SphK1 antisense, furthermore, nearly abrogated [Ca 2+ ] i increases by the complement component, C5a, in macrophages and strongly inhibited degranulation, cytokine release, and migration of these cells in response to C5a (Melendez and Ibrahim 2004) . Interestingly, SphK1-deficient mice had normal inflammatory responses (e.g., thioglycollate-induced peritonitis and collagen-induced arthritis; Michaud et al. 2006 ). Furthermore, formyl peptide was fully able to stimulate NADPH oxidase activity and activation of several kinases, among them ERK and p38, in SphK1 null neutrophils ). The latter is in agreement with previous studies in HL-60 cells, which demonstrated that specifically [Ca 2+ ] i increases and degranulation were dependent on SphK, but neither formyl peptide-stimulated superoxide production nor nucleotide-stimulated ERK, JNK, or p38 activation were affected by SphK inhibitors in these cells (Alemany et al. 1999 (Alemany et al. , 2000 . Nevertheless, an important role for SphK1 in inflammation could not be confirmed by studies in SphK1 null mice so far, although neither SphK2 was upregulated nor S1P degrading enzymes were downregulated for compensation . This is in clear contrast to studies in mast cells and macrophages in which SphK1 was reduced by antisense or siRNA (Olivera and Rivera 2005; Kee et al. 2005 ) and might be due to unknown adaptation processes.
Physiological and pathophysiological roles of SphKs
SphKs have been implicated in proliferation, survival, migration and regulation of Ca 2+ homoeostasis, development and regulation of the cardiovascular and nervous systems, inflammation, immunity, and cancer growth (Hait et al. 2006; Taha et al. 2006a ). S1P appears to be produced in vivo by SphKs; other pathways, for example cleavage of sphingosylphosphorylcholine by autotaxin (Clair et al. 2003) , have not been proven to occur within a living organism. Therefore, all actions of S1P might be directly or indirectly dependent on SphKs. In agreement, mouse embryos deficient in both SphK1 and SphK2 had no measurable S1P levels (Mizugishi et al. 2005) . Interestingly, SphK activity was substantially decreased in SphK1 −/− mice, whereas S1P tissue levels were essentially normal (Allende et al. 2004) , indicating that SphK1 deficiency could be compensated for. Merely in serum, S1P levels were reduced by ∼50% in SphK1 −/− mice (Allende et al. 2004; Zemann et al. 2006) . In comparison, in SphK2
mice, plasma S1P levels were reduced by only ∼25%, whereas serum levels were not reduced, indicating that both kinases, with predominance of SphK1, contributed to plasma and serum S1P (Kharel et al. 2005; Zemann et al. 2006) . However, it has to be considered that S1P levels are as well regulated by the degrading enzymes, S1P lyase and diverse phosphatases. The S1P lyase inhibitor, 2-acetyl-4-tetrahydroxybutylimidazole, greatly enhanced S1P levels in thymus, spleen, and lymph nodes (Schwab et al. 2005) , and depletion of SPP1 by siRNA elevated S1P levels in cell culture supernatants (Johnson et al. 2003) , indicating the importance of these enzymes in maintaining S1P homeostasis.
Genetic deletion of either SphK1 or SphK2 in the mouse caused no greater abnormalities (Allende et al. 2004; Michaud et al. 2006; Kharel et al. 2005; Zemann et al. 2006) . Furthermore, SphK1-deficient mice had normal acute and chronic inflammatory responses , see above. In contrast, deletion of both SphK1 and SphK2 led to embryonic lethality before day 13.5 because of severe bleeding (Mizugishi et al. 2005) . The wall of dorsal aorta was poorly developed, and the covering by vascular smooth muscle cells was incomplete, suggesting a migratory defect in smooth muscle cell precursors, as also observed in mice deficient in the S1P 1 receptor (Mizugishi et al. 2005; Liu et al. 2000b; Allende and Proia 2002) . SphK1
SphK2
−/− mice furthermore had a cranial neural tube defect, which occurred in 20% at embryonic day 12.5, indicating the importance of S1P for the development of the central nervous system (Mizugishi et al. 2005) . In agreement, SphK1 was found to be expressed in the whole embryonic mouse brain, with highest expression in telencephalon, whereas SphK2 expression was ubiquitous and highest in limb buds, eyes, and branchial arches. As in vascular development, the S1P 1 receptor was found to be required for normal neural development (Mizugishi et al. 2005) . SphKs furthermore play an important role in cancer growth and survival. SphK1 promotes cancer cell growth, enhances survival of chemotherapy-challenged cells, and stimulates or inhibits cancer cell motility (Hait et al. 2006) . In contrast, SphK2 enhances apoptosis, and this effect has been attributed to its BH3 domain (Liu et al. 2003) . As other BH3-only proteins, SphK2 interacted directly with the anti-apoptotic Bcl-x L , causing its inactivation (Liu et al. 2003) . In addition, the catalytic activity and specific subcellular localization contributed to the pro-apoptotic effect of SphK2 . SphK1, on the other hand, increased S1P levels, promoted G1/S transition, and stimulated cell growth when overexpressed in NIH3T3 cells (Olivera et al. 1999) . SphK1 overexpression furthermore stimulated colony formation in soft agar and tumor growth in immunodeficient mice, indicating an oncogenic role of SphK1 (Xia et al. 2000) . In NIH3T3 cells, SphK activity was specifically enhanced by expression of constitutively active Ras but not Src, whereas Ras-induced focus formation was inhibited by DMS and dominant negative SphK1, placing SphK1 downstream of Ras (Xia et al. 2000) . In contrast, VEGF-stimulated Ras activation in bladder carcinoma cells was inhibited by DMS, placing SphK upstream of Ras (Wu et al. 2003) . In MCF-7 breast cancer cells, overexpression of SphK1 delayed cell death induced by the anti-cancer drug, doxorubicin, and stimulated estrogen-dependent cell growth and tumor formation in mice (Nava et al. 2002) . Estrogen induced a biphasic elevation of SphK activity, and dominant negative SphK1 inhibited estrogen-dependent growth of MCF-7 cells (Sukocheva et al. 2003) . Recently, it was shown that estrogen induced transactivation of EGF receptors in MCF-7 cells via SphK1 and S1P 3 (Sukocheva et al. 2006) . Downregulation of SphK1 in MCF-7 cells by siRNA caused cell cycle arrest and apoptosis, demonstrating that endogenous SphK1 was required for survival of these cells (Taha et al. 2006c ). In prostate cancer cells, overexpression of SphK1 again protected against chemotherapeutics, and siRNA deletion of SphK1 induced apoptosis (Pchejetski et al. 2005) . Furthermore, camptothecin and docetaxel induced a strong inhibition of SphK1 in tumor cell lines that were sensitive to these drugs (Pchejetski et al. 2005) . SphK1 mRNA levels were elevated in several solid tumors (French et al. 2003) . Downregulation of the elevated SphK1 levels in colon adenocarcinomas by siRNA furthermore decreased, and overexpression of SphK1 stimulated, the expression of cyclooxygenase-2, which is a pathogenic factor in colon carcinogenesis (Kawamori et al. 2006) . Genetic deletion of SphK1 in a mouse model of intestinal adenomas resulted in suppression of adenoma size but not incidence . Not only the growth but also the migration of tumor cells was regulated by SphKs and S1P. The S1P-GPCRs differentially regulate cell migration, with S1P 1 -and S1P 3 -receptors stimulating and S1P 2 -receptors inhibiting migration (Anliker and Chun 2004; Ishii et al. 2004) . Therefore, tumor cell motility and invasiveness can be inhibited (Arikawa et al. 2003) or stimulated (Döll et al. 2005; Hait et al. 2005) by SphK or S1P, depending on the S1P-GPCR expression profile. For suppression of tumor growth and improvement of chemosensitivity, SphK inhibitors have been suggested (French et al. 2003 (French et al. , 2006 . Furthermore, a monoclonal anti-S1P antibody was recently described that substantially reduced tumor progression in several murine xenograft and allograft models (Visentin et al. 2006) . Not only anti-proliferative but also anti-angiogenic effects contributed to tumor growth inhibition by the anti-S1P antibody (Visentin et al. 2006) . S1P is an important mediator in the cardiovascular system (for review, see Alewijnse et al. 2004; Hla 2004) . S1P is an important survival factor for vascular endothelial cells, induces the expression of endothelial cell surface molecules, and controls vascular permeability (Hla 2004) . By differential interaction with endothelium and smooth muscle, S1P can cause vasoconstriction or relaxation (Alewijnse et al. 2004; Hla 2004; Watterson et al. 2005; Hemmings 2006 ). The S1P 1 receptor is essential for blood vessel maturation, whereas the S1P 3 receptor mediates NO production (Nofer et al. 2004; Tölle et al. 2005 ) and activation of I K.ACh by S1P and FTY720-phosphate (Himmel et al. 2000; Sanna et al. 2004; Forrest et al. 2004 ).
SphKs are involved in the control of vascular tone. The resting tone of resistance arteries was enhanced by overexpression of SphK1 and decreased by expression of dominant negative SphK1 (Bolz et al. 2003) . Similarly, [Ca 2+ ] i increases and vasoconstriction in response to elevated pressure were enhanced by SphK1 overexpression and reduced by dominant-negative SphK1 (Bolz et al. 2003; Keller et al. 2006) . Extracellular S1P mimicked the effect of SphK1 overexpression and elevated pressure induced a translocation of SphK1 from the cytosol to the membrane, suggesting that signaling inside-out takes place in this system (Bolz et al. 2003; Keller et al. 2006) . SphK was furthermore involved in endothelium-dependent vasorelaxation mediated by G q -coupled receptors. The contractile response of rat carotid arteries to angiotensin II, but not phenylephrine or KCl depolarization, was enhanced by the SphK inhibitor, DMS, in an endothelium-dependent manner (Mulders et al. 2006) . Furthermore, angiotensin II-stimulated NO release in endothelial cells was inhibited by DMS and a S1P 1/3 receptor antagonist, indicating the involvement of SphK and inside-out signaling in angiotensin IIstimulated NO release and vasorelaxation (Mulders et al. 2006) . This is in agreement with previous reports showing that extracellular S1P stimulated endothelial NO synthase (Igarashi et al. 2001; Nofer et al. 2004 ). Acetylcholineinduced vasorelaxation of precontracted rat aortic rings was reduced by the SphK inhibitor, threo-DHS (Roviezzo et al. 2006) . Extracellular S1P again imitated the effect, but relaxation by S1P was PTX-sensitive, whereas that by acetylcholine was not. Furthermore, threo-DHS also inhibited vasorelaxation by extracellular S1P, and it was concluded that not S1P-GPCR but intracellular S1P mediated the effect (Roviezzo et al. 2006) . The data are in agreement with the previously reported involvement of SphKs in Ca 2+ signaling by M 2 and M 3 receptors (Meyer zu Heringdorf et al. 1998) .
TNF-α, a key pro-inflammatory cytokine acting on the endothelium, stimulated SphK activity and S1P production in endothelial cells, and SphK inhibition reduced TNF-α-stimulated expression of adhesion molecules (E-selectin and vascular adhesion molecule-1; Xia et al. 1998 ). TNF-α-induced SphK activation was independent on sphingomyelinase and ceramidase activities (Xia et al. 1998 ). Other authors reported that TNF-α-stimulated NO synthase in endothelial cells was dependent on a sequential activation of neutral sphingomyelinase-2 and SphK1 (De Palma et al. 2006) . NO production by both TNF-α and extracellular S1P were sensitive to PTX, and the effect of TNF-α was abolished by combined antisense to S1P 1 and S1P 3 receptors, indicating inside-out signaling (De Palma et al. 2006) . Furthermore, TNF-α stimulated the adhesion of immature dendritic cells to endothelial cells, and expression of dominant negative SphK1 or NO synthase inhibition enhanced this effect, indicating a negative regulation of pro-inflammatory functions by the SphK/NO synthase pathway (De Palma et al. 2006) , in contrast to the previous studies (Xia et al. 1998) . A pro-inflammatory role for SphK in the endothelium was recently observed in hyperglycemia. High glucose levels upregulated SphK1 activity in rat aorta and heart, and SphK downregulation attenuated the endothelial expression of proinflammatory adhesion molecules and adhesion of leukocytes to endothelial cells .
Conclusions
Many actions have been ascribed to S1P, and SphKs have been identified as important players in the regulation of extracellular as well as intracellular S1P levels. However, the regulation of subcellular pools of S1P by the interplay of SphKs and S1P lyase/phosphatases clearly requires further analysis. Furthermore, the regulation of enzymes such as ceramidases, ceramide synthases, and ceramide kinase that drive the interconversion of S1P, sphingosine, ceramide, and ceramide-1-phosphate, are largely unknown. Several data show how SphK1 can be regulated at the molecular level, but the specific control of SphK1 activity and localization, for example by GPCRs, still remains not fully clear. Much less is even known about regulation of SphK2. One of the most important questions at present, however, might be whether there are other SphK isoforms. By functional studies using subcellular fractionation and diverse assay conditions, three diverse SphK activities were differentiated, all of which were inhibited by DMS (Gijsbers et al. 2001) . Although S1P levels in SphK1/2 double knockout mice embryos were not detectable, it cannot be excluded that expression of an additional SphK (s) might occur later during development. Searching for other SphK isoforms has already led to the discovery of a novel enzyme, a monoacylglycerol kinase that is related to SphKs and ceramide kinase (Bektas et al. 2005) . It may be evident from this review that even after decades of research, SphKs still remain enigmatic.
